Once-daily dasatinib for treatment of patients with chronic myeloid leukemia

Annals of Pharmacotherapy

Volumn 43, Issue 5, 2009, Pages 920-927

  Tyler, Timothy ^a  

^a DESERT REGIONAL MEDICAL CENTER   (United States)

Author keywords

Chronic myelogenous leukemia; Chronic myeloid leukemia; Dasatinib; Regimen; Schedule

Indexed keywords

DASATINIB; FAMOTIDINE; IMATINIB; NILOTINIB; OMEPRAZOLE;

ABDOMINAL PAIN; ANEMIA; ARTICLE; BLEEDING; CARDIOTOXICITY; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; COUGHING; CYTOPENIA; DISEASE SEVERITY; DOSE RESPONSE; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG FEVER; DRUG MECHANISM; DRUG SAFETY; DRUG SOLUBILITY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; GASTROINTESTINAL DISEASE; HUMAN; INFECTION; LEUKOPENIA; MEDICAL LITERATURE; MEDICAL RESEARCH; MEDICAL SOCIETY; PATIENT INFORMATION; PLEURA EFFUSION; PRIORITY JOURNAL; SIDE EFFECT; SWELLING; THROMBOCYTOPENIA; TREATMENT FAILURE; TREATMENT RESPONSE; WEIGHT GAIN;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; DRUG RESISTANCE, NEOPLASM; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; THIAZOLES;

EID: 65749087050     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1L570     Document Type: Article

References (47)

1. Frame D. Making strides in the management of chronic myeloid leukemia. Introduction. Am J Health Syst Pharm 2007;64(suppl):S2-3.
2. Lugo TG, Pendergast AM, Muller AJ, Witte ON. Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science 1990; 247:1079-1082 (Pubitemid 20102464)
3. Deininger MW, Goldman JM, Melo JV. The molecular biology of chronic myeloid leukemia. Blood 2000;96:3343-3356
4. Nowell PC, Hungerford DA. A minute chromosome in human chronic granulocytic leukemia (abstract). Science 1960;132:1497.
5. Kantarjian HM, Talpaz M, Giles F, O'Brien S, Cortes J. New insights into the pathophysiology of chronic myeloid leukemia and imatinib resistance. Ann Intern Med 2006;145:913-923
6. O'Brien SG, Guilhot F, Larson RA, Gathmann, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronicphase chronic myeloid leukemia. N Engl J Med 2003;348:994-1004.
7. O'Hare T, Walters DK, Stoffregen EP, et al. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib- resistant Abl kinase domain mutants. Cancer Res 2005;65:4500-4505
8. U.S. National Institutes of Health. www.clinicaltrials.gov (accessed 2008 Sept 12).
9. Kantarjian HM, Talpaz M, O'Brien S, et al. Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia. Blood 2003;101:473-475
10. Marin D, Goldman JM, Olavarria E, Apperley JF. Transient benefit only from increasing the imatinib dose in CML patients who do not achieve complete cytogenetic remissions on conventional doses. Blood 2003; 102:2702-2703 (Pubitemid 37193621)
11. Jabbour E, Kantarjian H, Atallah E, et al. Impact of imatinib mesylate dose escalation on resistance and sub-optimal responses to standard-dose therapy in patients (pts) with chronic myeloid leukemia (CML) (abstract 1035). Blood 2007;110:313a-4a.
12. Rousselot PH, Facon T, Paquette R, Bleickardt D, Kantarjian HM. Dasatinib or high-dose imatinib for patients with chronic myelogenous leukemia chronic-phase (CML-CP) resistant to standard-dose imatinib: 2-year follow-up data from START-R (abstract 7012). J Clin Oncol 2008;26:375s.
13. Cortes J, Kantarjian H. Response: dose escalation of imatinib may improve responses in patients with CML who fail standard-dose imatinib. Blood 2003;102:2703-2704
14. Zonder JA, Pemberton P, Brandt H, Mohamed AN, Schiffer CA. The effect of dose increase of imatinib mesylate in patients with chronic or accelerated phase chronic myelogenous leukemia with inadequate hematologic or cytogenetic response to initial treatment. Clin Cancer Res 2003;9:2092-2097 (Pubitemid 36687630)
15. Kantarjian HM, Giles F, Gattermann N, et al. Nilotinib (formerly AMN107), a highly selective Bcr-Abl tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood 2007;110:3540-3546
16. Kantarjian HM, Giles FJ, Hochhaus A, et al. Nilotinib in patients with imatinib-resistant or -intolerant chronic myelogenous leukemia in chronic phase (CML-CP): updated phase II results (abstract 7010). J Clin Oncol 2008;26:374s.
17. le Coutre P, Giles FJ, Apperley J, et al. Nilotinib in accelerated phase chronic myelogenous leukemia (CML-AP) patients with imatinib-resistance or -intolerance: update of a phase II study (abstract 7050). J Clin Oncol 2008;26:384s.
18. le Coutre P, Ottmann OG, Giles F, et al. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia. Blood 2008;111:1834-1839.
19. Shah NP, Tran C, Lee FY, Chen P, Norris D, Sawyers CL. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 2004;305: 399-401. (Pubitemid 38938156)
20. Brave M, Goodman V, Kaminskas E, et al. Sprycel for chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to or intolerant of imatinib mesylate. Clin Cancer Res 2008;14:352-359
21. Shah NP, Kantarjian HM, Kim DW, et al. Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia. J Clin Oncol 2008;26:3204-3212
22. Prescribing Information. Sprycel (dasatinib). Princeton, NJ: Bristol-Myers Squibb Company, May 2008.
23. Kamath AV, Wang J, Lee FY, Marathe PH. Preclinical pharmacokinetics and in vitro metabolism of dasatinib (BMS-354825): a potent oral multitargeted kinase inhibitor against SRC and BCR-ABL. Cancer Chemother Pharmacol 2008;61:365-376 Epub 2007 Apr 11. (Pubitemid 350275972)
24. Christopher LJ, Cui D, Wu C, et al. Metabolism and disposition of dasatinib after oral administration to humans. Drug Metab Dispos 2008;36: 1357-1364 Epub 2007 Apr 17.
25. Porkka K, Koskenvesa P, Lundán T, et al. Dasatinib crosses the bloodbrain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia. Blood 2008;112:1005-1012 Epub 2008 May 13.
26. Bristol Myers Squibb Company. Dasatinib (BMS-354825) Oncologic Drug Advisory Committee (ODAC) Briefing Document NDA 21-986. www.fda.gov/ohrms/ dockets/AC/06/briefing/2006-4220-B1-01Bristol MyersSquibb-Background.pdf (accessed 2008 Jun 9).
27. Hochhaus A, Kantarjian HM, Baccarani M, et al. Dasatinib induces notable hematologic and cytogenetic responses in chronic phase chronic myeloid leukemia after failure of imatinib therapy. Blood 2007;109: 2303-2309
28. Cortes J, Rousselot P, Kim DW, et al. Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or - intolerant chronic myeloid leukemia in blast crisis. Blood 2007;109: 3207-3213
29. Guilhot F, Apperley J, Kim DW, et al. Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase. Blood 2007;109:4143-4150
30. Ottmann O, Dombret H, Baccarani M, et al. Dasatinib induces rapid hematologic and cytogenetic responses in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a Phase II study. Blood 2007; 110:2309-2315 (Pubitemid 47523149)
31. Cortes J, Sawyers CL, Kantarjian HM, et al. Dasatinib is associated with durable treatment responses in chronic phase chronic myeloid leukemia: long-term follow-up from the phase I trial (CA180002) (abstract 0119). Haematologica 2008;93:47.
32. Mauro MJ, Baccarani M, Cervantes F, et al. Dasatinib 2-year efficacy in patients with chronic-phase chronic myelogenous leukemia (CML-CP) with resistance or intolerance to imatinib (START-C) (abstract). J Clin Oncol 2008;26:7009a.
33. Talpaz M, Shah NP, Kantarjian H, et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 2006;354: 2531-2541
34. Rea D, Dombret H, Kim DW, et al. Dasatinib efficacy in patients with imatinib-resistant/-intolerant chronic myeloid leukemia in accelerated phase 24-month data from START-A (abstract 0982). Haematologica 2008;93:391.
35. Saglio G, Dombret H, Rea D, et al. Dasatinib efficacy in patients with imatinib-resistant/-intolerant chronic myeloid leukemia in blast phase: 24-month data from the START program (abstract 0880). Haematologica 2008;93:349.
36. Porkka K, Martinelli G, Ottman OG, et al. Dasatinib efficacy in patients with imatinib-resistant/-intolerant Philadelphia-chromosome-positive acute lymphoblastic leukemia: 24-month data from START-L (abstract 0001). Haematologica 2008;93:1.
37. Kantarjian H, Pasquini R, Hamerschlak N, et al. Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial. Blood 2007;109:5143-5150 (Pubitemid 46890528)
38. ten Hoeve J, Arlinghaus RB, Guo JQ, Heisterkamp N, Groffen J. Tyrosine phosphorylation of CRKL in Philadelphia+ leukemia. Blood 1994; 84:1731-1736
39. Oda T, Heaney C, Hagopian JR, Okuda K, Griffin JD, Druker BJ. Crkl is the major tyrosine-phosphorylated protein in neutrophils from patients with chronic myelogenous leukemia. J Biol Chem 1994;269:22925-22928 (Pubitemid 24283264)
40. Nichols GL, Raines MA, Vera JC, Lacomis L, Tempst P, Golde DW. Identification of CRKL as the constitutively phosphorylated 39-kD tyrosine phosphoprotein in chronic myelogenous leukemia cells. Blood 1994;84:2912-2918 (Pubitemid 24328078)
41. Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001;344:1031-1037
42. Hochhaus A, Mueller M, Cortes JE, et al. Dasatinib efficacy by dosing schedule across individual baseline BCR-ABL mutations in chronic phase chronic myelogenous leukemia (CML-CP) after imatinib failure (abstract). J Clin Oncol 2008;26:7014a.
43. Wang X, Hochhaus A, Kantarjian HM, et al. Dasatinib pharmacokinetics and exposure-response (E-R): relationship to safety and efficacy in patients (pts) with chronic myeloid leukemia (CML) (abstract). J Clin Oncol 2008;26(suppl):3590.
44. Shah NP, Nicoll JM, Bleickardt E, et al. Potent transient inhibition of BCR-ABL by dasatinib leads to complete cytogenetic remissions in patients with chronic myeloid leukemia: implications for patient management and drug development (abstract 2166). Blood 2006;108:614a.
45. Prescribing information. Gleevec (imatinib). East Hanover, NJ: Novartis Pharmaceuticals Corporation, November 2006.
46. Kerkelä R, Grazette L, Yacobi R, et al. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med 2006;12:908-916
47. Prescribing information. Tasigna (nilotinib). East Hanover, NJ: Novartis Pharmaceuticals Corporation, October 2007.